Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility
The treatment of cystic fibrosis (CF) changed dramatically with the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies that address the underlying cause of the disease. With the approval of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA), CFTR modulators can now treat most people with CF (pwCF). Clinical benefits observed in trials and in real-world data demonstrate substantial improvements in lung function, pulmonary exacerbations, nutritional measures, and transplant and mortality outcomes in patients treated with ELX/TEZ/IVA [1,2].
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Jaime L. Rubin, James L. Kreindler Tags: Letter to the Editor Source Type: research
More News: Cystic Fibrosis | Lung Transplant | Nutrition | Respiratory Medicine | Transplant Surgery | Transplants